Literature DB >> 2332430

Biosynthesis of heparin. Availability of glucosaminyl 3-O-sulfation sites.

M Kusche1, G Torri, B Casu, U Lindahl.   

Abstract

Heparin preparations isolated from pig intestinal mucosa and from bovine lung were fractionated with regard to affinity for antithrombin. The resulting fractions, with high (HA) or low (LA) affinity for the proteinase inhibitor, were analyzed by 13C NMR or by identification of di- and tetrasaccharides obtained through deaminative cleavage with nitrous acid. Structural differences between corresponding HA and LA fractions were essentially restricted to minor constituents, in particular 3-O-sulfated glucosamine units that occurred (1 or 2 residues/chain) in all HA preparations but were scarce or absent in LA heparin. The HA fractions also consistently showed higher contents of nonsulfated iduronic acid and, to a lesser extent, N-acetylated glucosamine units than the LA fractions. The two tetrasaccharide sequences, -IdoA-GlcNAc(6-OSO3)-GlcA-GlcNSO3- and -IdoA-GlcNAc(6-OSO3)-GlcA-GlcNSO3(6-OSO3)- , recently implicated as part of the acceptor site for glucosaminyl 3-O-sulfate groups (Kusche, M., Bäckström, G., Riesenfeld, J., Petitou, M., Choay, J., and Lindahl, U. (1988) J. Biol. Chem. 263, 15474-15484), were identified in mucosal LA heparin; it was calculated that the preparation contained approximately one potential acceptor site/polysaccharide chain. Yet this material did not yield any labeled HA components on incubation with adenosine 3'-phosphate 5'-phospho-[35S]sulfate in the presence of glucosaminyl 3-O-sulfotransferase, solubilized from a mouse mastocytoma microsomal fraction. The failure to incorporate any 3-O-sulfate groups could conceivably be explained by the occurrence of a D-glucuronic rather than L-iduronic acid unit linked at the reducing ends of the above tetrasaccharide sequences. Alternatively, 3-O-sulfation may be restricted by other, as yet unidentified, inhibitory structural elements that are preferentially expressed in polysaccharide sequences selected for the generation of LA heparin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332430

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

2.  Heparin is a major activator of the anticoagulant serpin, protein Z-dependent protease inhibitor.

Authors:  Xin Huang; Alireza R Rezaie; George J Broze; Steven T Olson
Journal:  J Biol Chem       Date:  2011-01-10       Impact factor: 5.157

3.  Drosophila heparan sulfate, a novel design.

Authors:  Marion Kusche-Gullberg; Kent Nybakken; Norbert Perrimon; Ulf Lindahl
Journal:  J Biol Chem       Date:  2012-05-03       Impact factor: 5.157

4.  Biosynthesis of heparin. Use of Escherichia coli K5 capsular polysaccharide as a model substrate in enzymic polymer-modification reactions.

Authors:  M Kusche; H H Hannesson; U Lindahl
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

5.  Stable heparin-producing cell lines derived from the Furth murine mastocytoma.

Authors:  R I Montgomery; K Lidholt; N W Flay; J Liang; B Vertel; U Lindahl; J D Esko
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

6.  Heterogeneous distribution of antithrombin-binding sites in rat brain heparan sulphate proteoglycans.

Authors:  A A Horner
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

7.  Structural and functional properties of heparin analogues obtained by chemical sulphation of Escherichia coli K5 capsular polysaccharide.

Authors:  N Razi; E Feyzi; I Björk; A Naggi; B Casu; U Lindahl
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

8.  Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.

Authors:  Ernesto Luna; Pankaj Agrawal; Riyaz Mehta; Charlotte Vernhes; Christian Viskov; Jean Amiral; William L Warren; Donald R Drake
Journal:  Clin Appl Thromb Hemost       Date:  2014-12-18       Impact factor: 2.389

9.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.